Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.81 |
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.71 |
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.71 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | IDE | P14735 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28759648 | 0.89 | LMNA (0.76) | LMNASMN1; SMN2MAPTALDH1A1SLC6A9 | |
| SCHEMBL4421403 | 0.88 | LMNA (0.91) | LMNASMN1; SMN2MAPTALDH1A1SLC6A9 | |
| SCHEMBL4423014 | 0.85 | LMNA (1.00) | LMNASMN1; SMN2MAPTALDH1A1SLC6A9 | |
| SCHEMBL3924591 | 0.85 | SLC6A5 (0.85) | LMNASMN1; SMN2MAPTALDH1A1SLC6A9 | |
| SCHEMBL4426817 | 0.85 | LMNA (0.81) | LMNASMN1; SMN2MAPTALDH1A1SLC6A9 | |
| SCHEMBL5555422 | 0.84 | SLC6A5 (0.83) | LMNASMN1; SMN2MAPTALDH1A1SLC6A9 | |
| SCHEMBL3916574 | 0.83 | SLC6A5 (1.00) | SMN1; SMN2SLC6A9SLC6A5MAPK1IDE | |
| SCHEMBL27859058 | 0.81 | SLC6A5 (0.78) | LMNASMN1; SMN2MAPTALDH1A1SLC6A9 | |
| SCHEMBL4423549 | 0.81 | ALDH1A1 (0.83) | LMNASMN1; SMN2MAPTALDH1A1SLC6A9 | |
| SCHEMBL4423010 | 0.81 | SLC6A5 (0.74) | LMNASMN1; SMN2MAPTALDH1A1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100522171-C | 1-Benzoylpiperazine derivatives as glycine uptake inhibitors for the treatment of psychosis | HOFFMANN LA ROCHE (CH) | 2009-08-05 | — | — | CN | claimed |
| EP-1703909-B1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | claimed |
| JP-2007505062-A | — | — | 2007-03-08 | — | — | JP | claimed |
| CN-1878554-A | 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses | HOFFMANN LA ROCHE (CH) | 2006-12-13 | — | — | CN | claimed |
| EP-1703909-A1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-27 | — | — | EP | claimed |
| US-20050059668-A1 | Substituted acylpiperazine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | US | claimed |
| WO-2005023261-A1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | claimed |
| CN-100522171-C | 1-Benzoylpiperazine derivatives as glycine uptake inhibitors for the treatment of psychosis | HOFFMANN LA ROCHE (CH) | 2009-08-05 | — | — | CN | disclosed |
| EP-1703909-B1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-7462617-B2 | Substituted acylpiperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-09 | — | — | US | disclosed |
| CN-1878554-A | 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses | HOFFMANN LA ROCHE (CH) | 2006-12-13 | — | — | CN | disclosed |
| EP-1703909-A1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-27 | — | — | EP | disclosed |
| US-20050059668-A1 | Substituted acylpiperazine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | US | disclosed |
| WO-2005023261-A1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059668-A1 | Substituted acylpiperazine derivatives | AGPAT5, ACHE, GRIK5 | LMNA 4830/4885SMN1; SMN2 473/4885MAPT 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.